Literature DB >> 21156266

Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses.

Alice Charach1, Emanuela Yeung, Troy Climans, Erin Lillie.   

Abstract

OBJECTIVE: In recent years cohort studies have examined childhood attention-deficit/hyperactivity disorder (ADHD) as a risk factor for substance use disorders (SUDs) in adolescence and young adulthood. The long-term risk is estimated for development of alcohol, cannabis, combined alcohol and psychoactive SUDs, combined SUDs (nonalcohol), and nicotine use disorders in children with ADHD.
METHOD: MEDLINE, CINHAL, PsycINFO, and EMBASE were searched through October 2009; reference lists of included studies were hand-searched. Prospective cohort studies were included if they compared children with ADHD to children without, identified cases using standardized criteria by mean age of 12 years, followed participants until adolescence (nicotine use) or young adulthood (psychoactive substance use disorder, with and without alcohol, alcohol use disorder, cannabis use disorder), and reported SUD outcomes. Two independent reviewers examined articles and extracted and cross-checked data. Effects were summarized as pooled odds ratios (ORs) in a random effects model.
RESULTS: Thirteen studies were included. Only two of five meta-analyses, for alcohol use disorder (N = 3,184) and for nicotine use (N = 2,067), estimated ORs showing stability when evaluated by sensitivity analyses. Childhood ADHD was associated with alcohol use disorder by young adulthood (OR = 1.35, 95% confidence interval = 1.11-1.64) and with nicotine use by middle adolescence (OR = 2.36, 95% confidence interval = 1.71-3.27). The association with drug use disorder, nonalcohol (N = 593), was highly influenced by a single study.
CONCLUSIONS: Childhood ADHD is associated with alcohol and drug use disorders in adulthood and with nicotine use in adolescence.
Copyright © 2011 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21156266     DOI: 10.1016/j.jaac.2010.09.019

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  125 in total

1.  Aberrant glutamate signaling in the prefrontal cortex and striatum of the spontaneously hypertensive rat model of attention-deficit/hyperactivity disorder.

Authors:  Erin M Miller; Francois Pomerleau; Peter Huettl; Greg A Gerhardt; Paul E A Glaser
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

2.  Impact of ADHD and cannabis use on executive functioning in young adults.

Authors:  Leanne Tamm; Jeffery N Epstein; Krista M Lisdahl; Brooke Molina; Susan Tapert; Stephen P Hinshaw; L Eugene Arnold; Katerina Velanova; Howard Abikoff; James M Swanson
Journal:  Drug Alcohol Depend       Date:  2013-08-11       Impact factor: 4.492

3.  The International ADHD in Substance Use Disorders Prevalence (IASP) study: background, methods and study population.

Authors:  Geurt van de Glind; Katelijne Van Emmerik-van Oortmerssen; Pieter Jan Carpentier; Frances R Levin; Maarten W J Koeter; Csaba Barta; Sharlene Kaye; Arvid Skutle; Johan Franck; Maija Konstenius; Eli-Torild Bu; Franz Moggi; Geert Dom; Zolt Demetrovics; Mélina Fatséas; Arild Schillinger; Máté Kapitány-Fövény; Sofie Verspreet; Andrea Seitz; Brian Johnson; Stephen V Faraone; J Antoni Ramos-Quiroga; Steve Allsop; Susan Carruthers; Robert A Schoevers; Wim van den Brink
Journal:  Int J Methods Psychiatr Res       Date:  2013-09-11       Impact factor: 4.035

4.  Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: meta-analysis of 63 studies enrolling 11,788 patients.

Authors:  M Riera; X Castells; A Tobias; R Cunill; L Blanco; D Capellà
Journal:  Psychopharmacology (Berl)       Date:  2017-06-19       Impact factor: 4.530

5.  Specificity of expectancies prospectively predicting alcohol and marijuana use in adulthood in the Pittsburgh ADHD longitudinal study.

Authors:  Christine A P Walther; Sarah L Pedersen; Elizabeth Gnagy; William E Pelham; Brooke S G Molina
Journal:  Psychol Addict Behav       Date:  2019-01-14

6.  ADHD, Conduct Disorder, Substance Use Disorder, and Nonprescription Stimulant Use.

Authors:  Judith S Brook; Elinor B Balka; Chenshu Zhang; David W Brook
Journal:  J Atten Disord       Date:  2014-04-28       Impact factor: 3.256

Review 7.  The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders.

Authors:  Courtney A Zulauf; Susan E Sprich; Steven A Safren; Timothy E Wilens
Journal:  Curr Psychiatry Rep       Date:  2014-03       Impact factor: 5.285

Review 8.  Attention-deficit/hyperactivity disorder and risk of substance use disorder: developmental considerations, potential pathways, and opportunities for research.

Authors:  Brooke S G Molina; William E Pelham
Journal:  Annu Rev Clin Psychol       Date:  2014-01-15       Impact factor: 18.561

9.  Further Evidence for Smoking and Substance Use Disorders in Youth With Bipolar Disorder and Comorbid Conduct Disorder.

Authors:  Timothy E Wilens; Joseph Biederman; MaryKate Martelon; Courtney Zulauf; Jesse P Anderson; Nicholas W Carrellas; Amy Yule; Janet Wozniak; Ronna Fried; Stephen V Faraone
Journal:  J Clin Psychiatry       Date:  2016-10       Impact factor: 4.384

10.  Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.

Authors:  Brooke S G Molina; Stephen P Hinshaw; L Eugene Arnold; James M Swanson; William E Pelham; Lily Hechtman; Betsy Hoza; Jeffery N Epstein; Timothy Wigal; Howard B Abikoff; Laurence L Greenhill; Peter S Jensen; Karen C Wells; Benedetto Vitiello; Robert D Gibbons; Andrea Howard; Patricia R Houck; Kwan Hur; Bo Lu; Sue Marcus
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-02-08       Impact factor: 8.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.